Stock Ratings / Health Care / CNSY / financials

GUTS (52) SINT (37) CTSO (21) ICU (33) ⌘ Pro Terminal →

Cerenome Inc. (CNSY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.74 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cerenome Inc. (CNSY) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $13.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSY)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CNSY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.9M

FY24

Rev $5.8M

FY25

Rev $5.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$5.2M	52%	-80%	-$22.4M	-$20.8M	-45%
FY 2024	$5.8M	52%	-80%	-$13.0M	-$10.7M	-45%
FY 2023	$4.9M	52%	-80%	-$13.3M	-$12.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSY)

✓Walkthrough of CNSY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNSY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.66%▲ RESISTANCE BREAKOUT

2026-10-30O $1.76H $1.76L $1.66C $1.74VOL 47.7K

RES: $1.54SUP: $0.70SMA50: $2.12SMA200: $4.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNSY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNSY Butterfly Map → + Track CNSY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -10.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNSY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNSY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNSY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSY)

Health Care Rank #800 of 1016 ⚔️ GUTS vs CNSY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNSY vs. GUTS, SINT, CTSO, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cerenome Inc. (CNSY) ranks #800 by composite RQD confidence (36/100, grade D-) and #868 by equity capitalization ($13.2M). Within this direct 5-issuer industry benchmark cohort, CNSY leads on earnings valuation at N/A trailing P/E, while CNSY leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CNSY at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNSY ACTIVE Cerenome Inc.	D-	36/100	—	—	-35.0%	0.00%	$13.2M	Benchmark Subject
GUTS Fractyl Health Inc.	D+	52/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-cnsy →
SINT SiNtx Technologies Inc.	D-	37/100	—	45.3%	-35.0%	-1.15%	$13.0M	/sint-vs-cnsy →
CTSO Cytosorbents Corporation	E	21/100	—	71.5%	-35.0%	-16.03%	$13.9M	/ctso-vs-cnsy →
ICU SeaStar Medical Holding Corporation	E	33/100	—	95.7%	-35.0%	-6.85%	$12.2M	/icu-vs-cnsy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001095981

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerenome Inc. (CNSY) reported GAAP revenue of $5.2M (-10.5% vs. FY2024 revenue of $5.8M , and +6.1% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (-94.8% YoY). On the balance sheet, CNSY closed FY2025 with $16.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.2M	-$22.4M	-$20.8M	-$20.8M	$16.3M	—
FY2024 (FY)	2024-12-31	$5.8M	-$13.0M	-$10.6M	-$10.7M	$6.6M	—
FY2023 (FY)	2023-12-31	$4.9M	-$13.3M	-$12.9M	-$12.9M	—	—

3. CNSY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNSY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cerenome Inc. (NASDAQ: CNSY) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.74 (0.00% 1D, market cap $13.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNSY ranks #800 in composite RQD confidence.

How does CNSY compare to GUTS and SINT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CNSY carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GUTS (Fractyl Health Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and SINT (SiNtx Technologies Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, CNSY leads on earnings multiple (N/A) while CNSY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNSY?

Per CNSY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001095981), Cerenome Inc. generated $5.2M in revenue (-10.5% YoY), -$22.4M in net income, and -$20.8M in free cash flow against $16.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNSY trading relative to its 50-day, 200-day, and 52-week technical levels?

CNSY last traded at $1.74 (0.00% on volume of 39,000 shares), positioning the stock -17.92% below its 50-day simple moving average ($2.12) and -62.42% below its 200-day simple moving average ($4.63). Across its 52-week range of $1.49 to $19.00, CNSY sits at the 1.4% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.52 to $1.96).